Feyza HÜSREVOĞLU ESEN, Yasemin ALTUNER TORUN, Çiğdem KARAKÜKCÜ, Seçil KÖSE, Ahmet ŞEHRİYAROĞLU, Dilek KAFADAR, Aydın ESEN, Mehmet KÖSE

Gelsolin levels in patients with bronchiolitis

Bronchiolitis is the leading cause of hospitalization in infants. Biomarkerscan show severity of the disease and help in clinical management. In thisstudy, the aim was to determine the clinical predictiveness of plasma gelsolinlevels (pGSN) in acute bronchiolitis.From December 2013 to May 2014, 52 patients with bronchiolitis (aged 0.05).Recent studies reported that pGSN levels can be used as a biomarker insepsis, inflammation and injuries. In this study, we have demonstrated thatpGSN level is not a predictive biomarker of bronchiolitis and its severity.Hence, we hypothesized that pGSN levels can be used in bacterial infectionsrather than viral infections as a biomarker.

PDF

___

1. Ravaglia C, Poletti V. Recent advances in the management of acute bronchiolitis. F1000Prime Rep 2014; 6: 103.

2. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 1986; 78: 736-742.

3. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969-971.

4. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 1997; 25: 594-598.

5. Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999; 160(5 Pt 1): 1673-1681.

6. Peddada N, Sagar A, Ashish GR, Garg R. Plasma gelsolin: A general prognostic marker of health. Med Hypotheses 2012; 78: 203-210.

7. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007; 35: 849-855.

8. Christofidou-Solomidou M, Scherpereel A, Solomides CC, et al. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 2002; 50: 54-60.

9. Rothenbach PA, Dahl B, Schwartz JJ, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol (1985) 2004; 96: 25-31.

10. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis 1992; 145: 106-109.

11. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics 2013;132: 28-36.

12. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010; 375: 1545-1555.

13. Cohen TS, Bucki R, Byfield FJ, et al. Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine 2011; 54: 235-238.

14. Kose M, Elmas T, Gokahmetoglu S, et al. Predictive value of gelsolin for the outcomes of preterm neonates: A pilot study. Pediatr Int 2014; 56: 856-859.

15. Kulakowska A, Zajkowska JM, Ciccarelli NJ, Mroczko B, Drozdowski W, Bucki R. Depletion of plasma gelsolin in patients with tick-borne encephalitis and Lyme neuroborreliosis. Neurodegener Dis 2011; 8: 375-380.

16. Halis H, Gunes T, Korkut S, et al. In the diagnosis of neonatal sepsis importance of gelsolin and relationship with mortality and morbidity. Med Hypotheses 2016; 94: 77-80.